about
Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesImatinib mesylate, the first molecularly targeted gene suppressor.Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).Allogeneic hematopoietic stem cell transplantation.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideJAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.Non-myeloablative allogeneic hematopoietic stem cell transplantation.Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure.Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe.Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques.Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.Massive immune hemolysis after non-myeloablative allogeneic peripheral blood stem cell transplantation with minor ABO-incompatibility.Hematopoietic stem cell transplantation for hematological malignancies in Europe.EBMT activity survey 2004 and changes in disease indication over the past 15 years.Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey.Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma
P2860
Q27014857-33E8AD9A-80FB-4541-9FBC-8498E717DA5BQ34975667-DA9FFD5A-0373-4DB8-97DD-2D1AE5BC679BQ35102183-A9E90672-FA14-4A42-91C3-D7572B08B0D6Q35201902-5154F591-2EDD-4D55-BB4A-10EAD336F078Q35478934-2378F2CD-9DB9-4EF3-B5D5-CE7255FF4210Q36805838-C9921791-ED0E-4B9B-9B00-475FD0EBC566Q37308127-A25A2BDF-21CD-4421-82BF-2F869638C30DQ38472178-B58EB84D-D0A8-4F1B-99AE-71C422FE7CE3Q38488058-F10CBAA0-8CBA-4A2D-9F94-FB19985E25B7Q40548332-E7AE2700-10F1-4124-BFD6-0744384B0A38Q40644808-45F7F8E7-C6A5-4DB7-8473-153DB891CC05Q41296016-3AE1C5D7-6917-482B-BC7B-DB46C9050DCBQ43577899-BF4ED707-182F-4CC0-8636-7AEE26BCE0C1Q44119537-E9328090-5E0C-421F-90C0-222FD194C156Q44253909-08DFF3B7-530C-49C9-8A10-F316358F4034Q44398792-2664D417-49C0-4F12-85D4-C834DF4A79D3Q47908471-E935B4FC-3A2C-4C5A-92FF-EB0FA8757F9EQ50783390-8E084E3C-2820-46D6-8704-15EB954486E6Q55471780-B9434E65-133C-4AA8-939F-77FEF2014CF2Q57212292-AC2D0484-A8CE-4471-8A91-F9183B7D5FFD
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Non-myeloablative stem cell transplants.
@ast
Non-myeloablative stem cell transplants.
@en
Non-myeloablative stem cell transplants.
@nl
type
label
Non-myeloablative stem cell transplants.
@ast
Non-myeloablative stem cell transplants.
@en
Non-myeloablative stem cell transplants.
@nl
prefLabel
Non-myeloablative stem cell transplants.
@ast
Non-myeloablative stem cell transplants.
@en
Non-myeloablative stem cell transplants.
@nl
P2860
P1476
Non-myeloablative stem cell transplants.
@en
P2093
P2860
P356
10.1046/J.1365-2141.2000.02405.X
P407
P577
2000-10-01T00:00:00Z